塑料在食品包装中的主要要求被确定为足够的机械性能,屏障性能,热性能和加工性。根据为该项目生产的两种不同的PHBV,铸造的混合膜的总体状况分析了PHBV到包装溶液中的加工性。生物聚合物PLA和PBS是混合材料,因为PHBV作为独立材料的性质不足。这两部电影都带有质量的可见问题,指出了试点生产过程参数或材料混合兼容性的问题。现有文献强调了PHBV与PLA和PBS之间的混乱问题。
图 1. 不同 PHBV 膜表面和横截面 SEM 显微照片:a) PHBV_70:30 (CF:DMF)、b) PHBV_85:15 (CF:DMF)、c) PHBV_DMF、d) PHBV_DMSO;横截面:e) PHBV_70:30 (CF:DMF)、f) PHBV_85:15 (CF:DMF)、g) PHBV_DMF、h) PHBV_DMSO。所有图像的比例均为 20 µm。i) 不同 PHBV 膜的孔隙度。
图1:包装材料要求。.............................................................................. 9 Figure 2: PHAs Structure (Gomes Gradíssimo et al., 2020) .................................................... 12 Figure 3: PHBV structure (Boufarguine et al., 2013) .............................................................. 14 Figure 4:PLA structure (Boufarguine et al., 2013) .................................................................. 15 Figure 5:PBAT structure (Nobrega et al., 2012) ...................................................................... 19 Figure 6:Physical modification through blending will be used in our current project............. 23 Figure 7:Polymer blending ....................................................................................................... 24 Figure 8:Thermo Fisher Process 11 Extruder........................................................................... 25 Figure 9:Injection moulding ..................................................................................................... 25 Figure 10:conveyor belt section.41 Figure 24:TGA weight results 50%:50% blends ...................................................................... 41 Figure 25:TGA Derive weight, neat materials......................................................................... 42 Figure 26:TGA Derive weight 75%:25% blends..................................................................... 42............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ..................................................................................................................................................................................................................................................................................................................................................................................................................................... 75%的结晶度:25%混合物................................................................................................................................. ............................................................................... 34 Figure 17: Enthalpy cure for 75%:25% blends .................................................................................................................................................. 34 Figure 18: Enthalpy curve for 50%:50% blends ...................................................................... 34 Figure 19:FTIR neat materials ................................................................................................. 37 Figure 20:FTIR results, PHBV & PLA blends ........................................................................ 37 Figure 21:FTIR results, PHBV & PBAT blends ...................................................................... 38 Figure 22:TGA weight results, neat materials ......................................................................... 41 Figure 23: TGA weight results 75%:25% blends .
摘要:手术部位感染(SSI)在术后手术过程中经常发生,并且经常用口服抗生素治疗,这可能会引起某些副作用。可以通过将抗菌/抗炎药封装在手术缝合材料中,从而避免这种感染,从而使它们可以在伤口闭合期间更有效地在作用部位作用,从而避免术后细菌感染并扩散。这项工作旨在开发新型的基于生物的抗感染纤维的纱线作为预防手术部位感染的新型缝合材料。为此,使用特殊设计的纱线收集器基于基于飞行的相互缠绕的微纤维(1.95±0.22 µm)的纱线进行原位制造。电纺纱缝合线(直径为300–500 µm)由聚(3-羟基丁酸-CO-CO-3-羟基乙烯酸)制成,具有不同的3HV单元,并包含环氧氟化物(CPX)羟化力(CPX),作为抗虫的抗腐烂药物活性药物(API)。然后通过扫描电子显微镜,傅立叶变换红外光谱,广角X射线散射,差量扫描量热法和体外药物释放来分析纱线。还根据抗菌和机械性能分析了纱线。材料表征表明,不同的聚合物分子结构影响了已达到的聚合物结晶度,该聚合物结晶度与不同的药物洗脱谱相关。此外,这些材料表现出PHBV的固有僵硬行为,API进一步增强了PHBV。最后,所有纱线缝合物呈现出5天的时间释放,均与革兰氏阳性和革兰氏阴性致病细菌相关。结果在这项研究中突出了开发的抗菌电纺纱的潜力,作为预防手术感染的潜在创新缝合材料。